Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
A. Riedel & C. S. Leopold. (2005) Degradation of Omeprazole Induced by Enteric Polymer Solutions and Aqueous Dispersions: HPLC Investigations. Drug Development and Industrial Pharmacy 31:2, pages 151-160.
Read now
Read now
Chul Soon Yong, Jae-Hee Jung, Jong-Dal Rhee, Chong-Kook Kim & Han-Gon Choi. (2001) Physicochemical Characterization and Evaluation of Buccal Adhesive Tablets Containing Omeprazole. Drug Development and Industrial Pharmacy 27:5, pages 447-455.
Read now
Read now
A. G. Davidson & A. McCallum. (1996) A Survey of the Stability of Omeprazole Products from 13 Countries. Drug Development and Industrial Pharmacy 22:12, pages 1173-1185.
Read now
Read now
C. Cederberg, T. Andersson & I. Skånberg. (1989) Omeprazole: Pharmacokinetics and Metabolism in Man. Scandinavian Journal of Gastroenterology 24:sup166, pages 33-40.
Read now
Read now
H. Larsson, H. Mattsson & E. Carlsson. (1988) Gastric Acid Antisecretory Effect of Two Different Dosage Forms of Omeprazole during Prolonged Oral Treatment in the Gastric Fistula Dog. Scandinavian Journal of Gastroenterology 23:8, pages 1013-1019.
Read now
Read now
Articles from other publishers (62)
Makoto Kataoka, Yoshiya Itaka, Takato Masada, Keiko Minami, Haruki Higashino & Shinji Yamashita. (2024) Near-infrared imaging of in vivo performance of orally administered solid forms to rats: Feasibility study with indocyanine green. International Journal of Pharmaceutics 649, pages 123677.
Crossref
Crossref
Annika Elbe, Kathrin Isabelle Foerster, Antje Blank, Peter Rose, Jürgen Burhenne, Walter Emil Haefeli & Gerd Mikus. (2022) Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. European Journal of Clinical Pharmacology 78:6, pages 975-987.
Crossref
Crossref
Ajinkya Trimukhe, Satish Rojekar, Pradeep R. Vavia & R.R. Deshmukh. (2021) Pulsed plasma surface modified omeprazole microparticles for delayed release application. Journal of Drug Delivery Science and Technology 66, pages 102905.
Crossref
Crossref
Alireza Khatibi, Payam Zahedi, Hedayatollah Ghourchian & Atefe Sadeghi Lari. (2021) Development of microfluidic-based cellulose acetate phthalate nanoparticles containing omeprazole for antiulcer activity: In vitro and in vivo evaluations. European Polymer Journal 147, pages 110294.
Crossref
Crossref
Federica Ronchi, Antonio Sereno, Maxime Paide, Pierre Sacré, George Guillaume, Vincent Stéphenne, Jonathan Goole & Karim Amighi. (2019) Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form. International Journal of Pharmaceutics 567, pages 118416.
Crossref
Crossref
Elena Puris, Markku Pasanen, Veli‐Pekka Ranta, Mikko Gynther, Aleksanteri Petsalo, Pirjo Käkelä, Ville Männistö & Jussi Pihlajamäki. (2019) Laparoscopic Roux‐en‐Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic & Clinical Pharmacology & Toxicology.
Crossref
Crossref
Tae Kim, Subindra Thapa, Da Lee, Seung Chung, Jun Lim, Hyeon Jeong, Chang Song, Youn-Woong Choi, Sang-Min Cho, Kyu-Yeol Nam, Won-Ho Kang, Soyoung Shin & Beom Shin. (2018) Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats. Pharmaceutics 10:3, pages 152.
Crossref
Crossref
Andressa Veiga, Paulo R. Oliveira, Larissa S. Bernardi, Cassiana Mendes, Marcos A. S. Silva, Maximiliano S. Sangoi, Paulo R. Janissek & Fábio S. Murakami. (2017) Solid-state compatibility studies of a drug without melting point. Journal of Thermal Analysis and Calorimetry 131:3, pages 3201-3209.
Crossref
Crossref
John Chung & Filippos Kesisoglou. (2018) Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions. Journal of Pharmaceutical Sciences 107:1, pages 18-23.
Crossref
Crossref
Mohammad Sofiqur Rahman, Naoko Yoshida, Hirohito Tsuboi, Tep Keila, Tey Sovannarith, Heng Bun Kiet, Eav Dararth, Theingi Zin, Tsuyoshi Tanimoto & Kazuko Kimura. (2017) Erroneous formulation of delayed-release omeprazole capsules: alert for importing countries. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
Ping Ren, Minglei Cui, Om Anand, Li Xia, Zhuojun J. Zhao, Dajun Sun, Trueman Sharp, Dale P. Conner, John Peters, Wenlei Jiang, Ethan Stier & Xiaojian Jiang. (2017) In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration. The AAPS Journal 19:6, pages 1593-1599.
Crossref
Crossref
Jens Van Den Abeele, Jari Rubbens, Joachim Brouwers & Patrick Augustijns. (2017) The dynamic gastric environment and its impact on drug and formulation behaviour. European Journal of Pharmaceutical Sciences 96, pages 207-231.
Crossref
Crossref
Ching Kim Tye, Zhanbin Wang, Randy C. Dockens, Blisse Vakkalagadda, Chunlei Wang, Yingru Zhang, Ching Chiang Su & Michael J. Hageman. (2016) Pre-absorption physicochemical compatibility assessment of 8-drug metabolic cocktail. International Journal of Pharmaceutics 514:2, pages 364-373.
Crossref
Crossref
Yohei Kosugi, Syunsuke Yamamoto, Noriyasu Sano, Atsutoshi Furuta, Tomoko Igari, Yasushi Fujioka & Nobuyuki Amano. (2015) Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. Journal of Pharmaceutical Sciences 104:9, pages 2887-2893.
Crossref
Crossref
Vishnu Dutt Sharma, Suleyman Akocak, Marc A. Ilies & Reza Fassihi. (2015) Solid-State Interactions at the Core-Coat Interface: Physicochemical Characterization of Enteric-Coated Omeprazole Pellets Without a Protective Sub-Coat. AAPS PharmSciTech 16:4, pages 934-943.
Crossref
Crossref
Claudia Suenderhauf, Gerald Tuffin, Helle Lorentsen, Hans-Peter Grimm, Christophe Flament & Neil Parrott. (2014) Pharmacokinetics of Paracetamol in Göttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption. Pharmaceutical Research 31:10, pages 2696-2707.
Crossref
Crossref
N.L. Parente, N. Bari Olivier, K.R. Refsal & C.A. Johnson. (2014) Serum Concentrations of Gastrin after Famotidine and Omeprazole Administration to Dogs. Journal of Veterinary Internal Medicine 28:5, pages 1465-1470.
Crossref
Crossref
Min Li. 2012. Organic Chemistry of Drug Degradation. Organic Chemistry of Drug Degradation
262
277
.
C. Rand, S. D. Stanley & N. Pusterla. (2011) Effects of intrarectally administered omeprazole paste on gastric fluid pH in healthy adult horses. Veterinary Record 169:5, pages 126-126.
Crossref
Crossref
Sven Stegemann. 2011. Controlled Release in Oral Drug Delivery. Controlled Release in Oral Drug Delivery
277
298
.
T. MARMULAK, S. STANLEY, P. H. KASS, V. WIEBE, D. McKEMIE & N. PUSTERLA. (2010) Pharmacokinetics of intrarectal omeprazole in alpacas. Journal of Veterinary Pharmacology and Therapeutics.
Crossref
Crossref
Wei HeLi-Fang Fan, Qing Du, Bai Xiang, Chun-Lei LiMin BaiYong-Zhen Chang & De-Ying Cao. (2009) Design and in Vitro/in Vivo Evaluation of Multi-layer Film Coated Pellets for Omeprazole. Chemical and Pharmaceutical Bulletin 57:2, pages 122-128.
Crossref
Crossref
Bertil Abrahamsson & Hans Lennernäs. 2008. Drug Bioavailability. Drug Bioavailability
521
558
.
S. Agatonovic-Kustrin, N. Markovic, M. Ginic-Markovic, M. Mangan & B.D. Glass. (2008) Compatibility studies between mannitol and omeprazole sodium isomers. Journal of Pharmaceutical and Biomedical Analysis 48:2, pages 356-360.
Crossref
Crossref
Takenori Niioka, Tsukasa Uno, Katsuyoshi Sugimoto, Kazunobu Sugawara, Makoto Hayakari & Tomonori Tateishi. (2007) Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. European Journal of Clinical Pharmacology 63:11, pages 1031-1038.
Crossref
Crossref
Katherine K. Williamson, Michael D. Willard, Erica C. McKenzie, Christopher M. Royer, Mark E. Payton & Michael S. Davis. (2008) Efficacy of Famotidine for the Prevention of Exercise‐Induced Gastritis in Racing Alaskan Sled Dogs. Journal of Veterinary Internal Medicine 21:5, pages 924-927.
Crossref
Crossref
A. Stroyer, J.W. McGinity & C.S. Leopold. (2006) Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers. Journal of Pharmaceutical Sciences 95:6, pages 1342-1353.
Crossref
Crossref
John W Devlin, Lynda S Welage & Keith M Olsen. (2005) Proton Pump Inhibitor Formulary Considerations in the Acutely III: Part 1: Pharmacology, Pharmacodynamics, and Available Formulations. Annals of Pharmacotherapy 39:10, pages 1667-1677.
Crossref
Crossref
Curtis E. Haas, Lydia Lin, Denise Cloen, Thomas Kufel, Richard Moon & Valerie Frerichs. (2005) Omeprazole Absorption from a Compounded Transdermal Formulation in Healthy Volunteers. Journal of the American Pharmacists Association 45:4, pages 473-478.
Crossref
Crossref
Eivor Örnskov, Anna Linusson & Staffan Folestad. (2003) Determination of dissociation constants of labile drug compounds by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 33:3, pages 379-391.
Crossref
Crossref
Henderik W. Frijlink. (2003) Benefits of different drug formulations in psychopharmacology. European Neuropsychopharmacology 13, pages 77-84.
Crossref
Crossref
Lynda S Welage. (2003) Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice. Gastroenterology Clinics of North America 32:3, pages S25-S35.
Crossref
Crossref
Jorge E. Nieto, Sharon Spier, Frank S. Pipers, Scott Stanley, Monica R. Aleman, Donald C. Smith & Jack R. Snyder. (2002) Comparison of paste and suspension formulations of omeprazole in the healing of gastric ulcers in racehorses in active training. Journal of the American Veterinary Medical Association 221:8, pages 1139-1143.
Crossref
Crossref
Edemilson Cardoso da Conceição, Tadao Shuhama, Clarice Izumi & Osvaldo de Freitas. (2001) Iron supplementation prevents the development of iron deficiency in rats with omeprazole-induced hypochlorhydria. Nutrition Research 21:8, pages 1201-1208.
Crossref
Crossref
Han-Gon Choi & Chong-Kook Kim. (2000) Development of omeprazole buccal adhesive tablets with stability enhancement in human saliva. Journal of Controlled Release 68:3, pages 397-404.
Crossref
Crossref
Han-Gon Choi, Jac-Hee Jung, Chul Soon Yong, Chong-Dal Rhee, Mi-Kyung Lee, Jeong-Hee Han, Kyung-Mi Park & Chong-Kook Kim. (2000) Formulation and in vivo evaluation of omeprazole buccal adhesive tablet. Journal of Controlled Release 68:3, pages 405-412.
Crossref
Crossref
Tsai, Poon, Yu, Chang, Yeh, Ko & Chen. (2000) Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients. Alimentary Pharmacology & Therapeutics 14:1, pages 123-127.
Crossref
Crossref
G. Garcı́a-Encina, R. Farrán, S. Puig & L. Martı́nez. (1999) Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis 21:2, pages 371-382.
Crossref
Crossref
C. P. DAURIO, J. E. HOLSTE, F. M. ANDREWS, A. M. MERRITT, J. T. BLACKFORD, F. DOLZ & D. R. THOMPSON. (2010) Effect of omeprazole paste on gastric acid secretion in horses. Equine Veterinary Journal 31:S29, pages 59-62.
Crossref
Crossref
O. V. Nikiforova, V. V. Chistyakov, E. V. Shikh & A. P. Arzamastsev. (1999) Pharmacokinetics and bioaccessibility of gastrozole. Pharmaceutical Chemistry Journal 33:4, pages 173-176.
Crossref
Crossref
A. Tivesten, S. Folestad, V. Schönbacher & K. Svensson. (1999) Nonaqueous capillary electrophoresis for the analysis of labile pharmaceutical compounds. Chromatographia 49:S1, pages S7-S11.
Crossref
Crossref
Åke G. Pilbrant. 1999. Proton Pump Inhibitors. Proton Pump Inhibitors
161
169
.
Rohan Elliott. (1998) Nasogastric Administration of Omeprazole. The Australian Journal of Hospital Pharmacy 28:3, pages 174-176.
Crossref
Crossref
Paolo L Peghini, Philip O Katz, Nicole A Bracy & Donald O Castell. (1998) Nocturnal Recovery of Gastric Acid Secretion With Twice-Daily Dosing of Proton Pump Inhibitors. American Journal of Gastroenterology 93:5, pages 763-767.
Crossref
Crossref
Mi-Sook Choi, Suk-Jae Chung & Chang-Koo Shim. (1996) Rectal Absorption of Omeprazole from Suppository in Humans. Journal of Pharmaceutical Sciences 85:8, pages 893-894.
Crossref
Crossref
Curtis Larson, Nicholas J. Cavuto, David A. Flockhart & Richard B. Weinberg. (1996) Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Digestive Diseases and Sciences 41:3, pages 475-479.
Crossref
Crossref
Kyong-Hoon Eun, Yong-Hee Lee & Chang-Koo Shim. (1995) Rectal absorption of omeprazole from suppositories in rabbits. Archives of Pharmacal Research 18:4, pages 219-223.
Crossref
Crossref
Kazuhide Watanabe, Katsushi Furuno, Kohei Eto, Ryozo Oishi & Yutaka Gomita. (1994) First-Pass Metabolism of Omeprazole in Rats. Journal of Pharmaceutical Sciences 83:8, pages 1131-1134.
Crossref
Crossref
Andreas W. Herling & Klaus Weidmann. 1994.
233
264
.
Firouzan Massoomi, John Savage & Christopher J. Destache. (2012) Omeprazole: A Comprehensive Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 13:1, pages 46-59.
Crossref
Crossref
Kaoru Kobayashi, Kan Chiba, Dong-Ryul Sohn, Yuriko Kato & Takashi Ishizaki. (1992) Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. Journal of Chromatography B: Biomedical Sciences and Applications 579:2, pages 299-305.
Crossref
Crossref
Isamu Aoki, Minoru Okumura & Takatsuka Yashiki. (1991) High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. Journal of Chromatography B: Biomedical Sciences and Applications 571:1-2, pages 283-290.
Crossref
Crossref
Torbjörn Arvidsson, Elisabeth Collijn, Anna-Maria Tivert & Lena Rosén. (1991) Peak distortion in the column liquid chromatographic determination of omeprazole dissolved in borax buffer. Journal of Chromatography A 586:2, pages 271-276.
Crossref
Crossref
Umesh BanakarSantosh Vetticaden. 1991. Pharmaceutical Dissolution Testing. Pharmaceutical Dissolution Testing
391
411
.
K Hirai, H Koike, T Ishiba, S Ueda, I Makino, H Yamada, T Ichihashi, Y Mizushima, M Ishikawa, Y Ishihara, Y Hara, H Hirose, N Shima & M Doteuchi. (1991) Amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole as acid-stable prodrugs of potential inhibitors of H+K+ ATPase. European Journal of Medicinal Chemistry 26:2, pages 143-158.
Crossref
Crossref
MS Ching, GW Mihaly, PW Angus, DJ Morgan, S. Devenish‐Meares, ND Yeomans & RA Smallwood. (2012) Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.. British Journal of Clinical Pharmacology 31:2, pages 166-170.
Crossref
Crossref
Tommy Andersson, Christer Cederberg, Asger Heggelund & Per Lundborg. (2012) The Pharmacokinetics of Single and Repeated Once-Daily Doses of 10, 20 and 40mg Omeprazole as Enteric-Coated Granules. Drug Investigation 3:1, pages 45-52.
Crossref
Crossref
Thomas A. Lampkin, Daniele Ouellet, Lawrence J. Hak & George E. Dukes. (2016) Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders. DICP 24:4, pages 393-402.
Crossref
Crossref
Haile T. Debas & Michael W. Mulholland. (1989) Drug therapy in peptic ulcer disease. Current Problems in Surgery 26:1, pages 9-54.
Crossref
Crossref
R. F. McKEE, A. J. MacGILCHRIST, O. J. GARDEN, J. A. H. FORREST & D. C. CARTER. (2007) The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease. Alimentary Pharmacology & Therapeutics 2:5, pages 429-437.
Crossref
Crossref
HA Tuynman, HP Festen, K Rohss & SG Meuwissen. (2012) Lack of effect of antacids on plasma concentrations of omeprazole given as enteric‐coated granules.. British Journal of Clinical Pharmacology 24:6, pages 833-835.
Crossref
Crossref
Susumu OKABE, Yasushi AKIMOTO, Hiroki MIYAKE & Junko IMADA. (1987) Effects of NC-1300 and Its Degradation Products on Gastric Secretion and HOEthanol-lnduced Gastric Lesions in Rats. Japanese Journal of Pharmacology 44:1, pages 7-14.
Crossref
Crossref